ArticleJAMA network open2025
Delayed Venous Thromboembolism Diagnosis and Mortality Risk.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring primary care providers' perspectives on clinical decision support for venous thromboembolism diagnosis: a qualitative study.BMJ open · 2026Article
- Clinical applications of PET imaging for evaluating treatment-induced vascular toxicity in oncology.Current opinion in hematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Nonspecific symptoms of venous thromboembolism (VTE) hinder timely recognition, and no automated tools exist to monitor diagnostic delay. Objective: To evaluate rates of diagnostic delay of VTE (DOVE) at 2 health care systems using different electronic health record (EHR) systems, to categorize missed diagnoses, and to assess the association of diagnostic delays with 30-day all-cause mortality. Design, Setting, and Participants: This diagnostic study used retrospective EHR data from Mass General Brigham (MGB) and Penn State Health (PSH). For MGB, data from 2016 to 2021 were extracted, whereas for PSH, data from 2019 to 2022 data were used. An electronic clinical quality measure (eCQM) was developed and used to quantify DOVE. The eCQM analyses were conducted from 2020 to 2022 at MGB and from 2022 to 2023 at PSH; mortality analyses were conducted from 2023 to 2024. Patients with VTE and documented VTE-related symptoms in primary care were included. Exposure: Diagnosis of VTE. Main Outcomes and Measures: The primary outcomes were DOVE rates and 30-day all-cause mortality by time to diagnosis. DOVE rates were calculated using thresholds of greater than 24 hours and greater than 72 hours, validated through EHR review. Missed opportunities were categorized into system, practitioner, patient, and other unclassified factors. Thirty-day all-cause mortality and risk ratios (RRs) were compared between timely (≤24 hours) and delayed (>24 hours) diagnosis. Results: A total of 3525 patients were included; 3281 patients (mean [SD] age, 65.95 [15.14] years; 1692 [51.57%] female) were from MGB, and 244 patients (mean [SD] age, 65.34 [16.76] years; 128 [52.46%] female) were from PSH. DOVE eCQM rates using the greater than 24-hour definition were 79.43% (95% CI, 78.00%-81.00%) for MGB and 82.38% (95% CI, 77.00%-87.00%) for PSH. The DOVE rate using the greater than 72-hour definition was 69.89% (95% CI, 68.00%-71.00%) for MGB and 71.31% (95% CI, 65.00%-77.00%) for PSH. Practitioner-related delays were most common. At MGB, mortality increased from 17 deaths (2.52%) for timely diagnosis to 217 deaths (8.33%) for delayed diagnoses, with an RR of 3.31 (95% CI, 2.03-5.38). At PSH, mortality increased from 2 deaths (4.65%) to 12 deaths (5.97%) with an RR of 1.28 (95% CI, 0.30-5.53). Diagnosis at less than 24 hours was often associated with missed pulmonary embolism leading to death. Conclusions and Relevance: In this diagnostic study of delayed VTE diagnosis, consistently high DOVE rates and associated increases in all-cause mortality support the use of the DOVE eCQM tool to guide quality improvement efforts at institutional, regional, and national levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.